SLFN11 repression occurs frequently in talazoparib-resistant cancer cell lines and was linked with impaired S-phase arrest and G2 progression, which may also be due to fork stabilization (Murai et al. 2016, 2018). The gene discussed is SLFN11; the disease is cancer.